Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...
Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.
The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.
The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...
The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.
The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...
The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...
News Medical on MSN3d
Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman's Health Imperative-and the National Association of ...
Discover eight promising respiratory disease companies advancing their novel therapies through clinical trials in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback